CREUTZFELDT-JAKOB DISEASE (CJD) is a rare and usually rapidly fatal neurodegenerative condition that occurs worldwide. It is characterised clinically by progressive dementia, ataxia and myoclonus. The classical neuropathological triad is spongiform degeneration of grey matter, neuronal loss and gliosis. The preceding textbook description belies a disorder which has, by a large margin, the highest interest factor (number of publications per case) of any disease,' has spawned a couple of Nobel prizes (one for studying a form acquired by cannibalism) and is the only human condition that can occur sporadically or as an infection or due to an inherited genetic mutation (with all forms of this paradoxical trinity being experimentally transmissible). Moreover, the infective agent is highly resistant to decontamination procedures (even surviving temperatures that can tum tissue to ash-) transmission can occur accidentally via medical procedures (over 260 deaths to date') and theoretically persons could unwittingly be asymptomatic carriers of infection for many years (or even decades). To add to these concerns, there is no presymptomatic test, no effective treatment and the nature ofthe infective agent remains elusive. And then, of course, there is bovine spongiform encephalopathy (BSE), the tragic death of over 110 young people to a related zoonosis (with the worry of a large future epidemic still looming) and the loss to the UK economy of £5 billion and counting.'
What causes CJD?
CJD is a member of a group ofconditions collectively labelled transmissible spongiform encephalopathies (TSEs) by some and prion diseases by others. The first of this group to be described was sheep scrapie in 1732. The other animal TSEs have only been recognised in the past 40 years and include transmissible mink encephalopathy, chronic wasting disease in deer and elk, BSE and feline spongiform encephalopathy. A major leap forward in understanding the nature of these disorders came in the 1930s when scrapie was shown to be experimentally transmissible between sheep, albeit with an incubation period in excess ofone year.' This finding supported the later concept of the slow transmissible agent, considered most likely to be a virus (hence these diseases were often referred to a slow virus diseases ). However, no such virus could be identified, and infection survived despite tissue being bombarded with ionizing or ultraviolet radiation, or multiple other insults that would be expected to slay a conventional virus (or any other living organism). A wild, but beautiful, hypothesis emerged in the late 1960s suggesting that the infective agent may be devoid of nucleic acid and contain only protein. This theory was championed by the Californian (later Nobel-prize winning) neurologist Stanley Prusiner who weathered a storm of derision from many of his contemporaries to show that a protein did indeed playa key role in the pathogenesis ofTSEs.
In 1982 Prusiner termed this the prion protein (PrP), short for proteinaceous infectious particle with the i and the 0 switched for convenience.' Prusiner s deep conviction that this protein was the fundamental part of the agent was strengthened by the discovery of the gene which codes for PrP on the short arm of chromosome 20 and the linkage ofa mutation of this gene to a familial form of human TSE called Gerstmann-Str ussler-Scheinker disease."
It is now known that PrP is normally a harmless cellular 100 Scot Med J 47; 5: 2002 component found in all animals, but one which twists into a pathological form in the disease state. The protein-only or prion hypothesis states that when abnormal PrP is produced it can act as a template for the conversion of more normal PrP to the twisted pathological form, hence setting in motion a chain reaction that can spread disease from cell to cell without the need for an infective organism. This theory has now become the conventional dogma, and elegantly provides a unified theory to explain the paradoxical trinity ofCJD: 1) the mutations associated with the hereditary TSEs renders PrP inherently unstable, with a high tendency to fold into the pathological isoform and initiate the chain reaction, 2) in sporadic disease the initial pathogenic PrP needed to seed the chain reaction occurs as a rare spontaneous event, and 3) in the infective form of the disease the inoculated pathogenic PrP initiates the chain reaction. However, although there is no doubt that prion protein plays a key role in the pathogenesis ofTSEs, the definitive experiment to prove that only protein is required for infection -converting normal to infective PrP in a test tube -has not been achieved. Thus the jury is still out on the prion hypothesis and some still believe that an additional nucleic acid-containing agent is required for infection.'
What are the clinical features of CJD?
The typical neurologist sees a patient with CJD every couple of years or so, whereas a general physician may (but probably won t) look after one case during their career and a general practitioner will encounter a patient every 500 years. However, many clinicians are likely to be asked: "Could it be mad cow disease doctor?" Thus, for most us, the main reason for being familiar with the clinical characteristics ofCJD is to be able to rule it out. CJD had historically been used as a convenient dumping ground diagnosis for many patients with atypical presenile dementias which run a rapid course. However, over the past 20 years the clinical features of over 1000 cases have been published, establishing a clear picture ofthe phenotypical range of disease. The majority (66%) ofcases currently seen in UK are sporadic, about 26% are variant CJD and the remainder are familial or iatrogenic. A history ofgrowth hormone exposure, neurosurgery or corneal transplantation characterises the latter, and many (but far from all) of the familial cases will have other affected family members, although often with what was considered to be another form ofdementia or psychiatric disorder.
Sporadic CJD characteristically affects persons in the age range 50-80 and can present with a protean range of symptoms.' However, the vast majority first have (in order of decreasing frequency) cognitive symptoms, unsteadiness or visual disturbance (including blurring, field defects). 7 Due to the rapid nature ofthe disease most suffers will deteriorate over the space of weeks and will have early objective evidence of cognitive impairment and soon develop neurological signs, most often in the form of ataxia. Thus a patient complaining of neurological symptoms, without objective evidence ofcognitive impairment is unlikely to have sporadic CJD, particularly ifthey fail to show evidence of cognitive decline over the ensuring weeks. Variant CJD typically affects a younger age group (13-45 years)," although a case aged 74 has been reported." The early clinical evolution is relatively distinct from sporadic CJD: presentation is usually with psychiatric symptoms (dysphoria, \" ': ) withdrawal, anxiety, insomnia, and loss ofinterest) or less often persistent painful sensory disturbance (pain, paraesthesia, dysaesthesia or burning in the limbs, body or face ).10 Neurological signs occur on average about five months from onset, most often in the form of gait disturbance. At a similar stage, symptoms ofcognitive impairment often occur.
All cases that underwent neuropsychometry had clear abnormalities, although assessments were only performed several months after the onset of symptoms and therefore it is unclear whether cognitive impairment is a very early sign. The early psychiatric symptoms of variant CJD are non-specific, but the failure to develop persistent painful sensory disturbance, unsteadiness or cognitive impairment after several months argues against the diagnosis. The later stages of variant and sporadic CJD are similar, with increasing global cognitive dysfunction, ataxia, dependency and urinary incontinence, culminating in the patient becoming bedbound, mute and unresponsive. Involuntary movements, typically myoclonus, nearly always develop as the illness progresses. A minority ofvariant CJD patients developed chorea or dystonia, and some had evidence of upgaze paresis. The median duration of illness in sporadic and variant CJD is 4.5 and 13 months respectively, the longer duration in the latter being largely due to the psychiatric prodrome and probably also the ability ofyounger persons to survive the complications ofdebility.
How can CJD be diagnosed?
Traditionally the diagnostic armoury for sporadic CJD has consisted of electroencephalography (EEG - Fig. 1 ) and brain biopsy, with post-mortem neuropathology being the gold standard. Although the latter remains true, the EEG is hampered by poor sensitivity (only about two-thirds of cases have a characteristic periodic tracing J J ) and the use ofbrain biopsy (a potentially dangerous procedure) purely to confirm a diagnosis ofCJD, an untreatable condition, is now frowned upon. Fortunately two readily available techniques have now been shown to be useful in separating true CJD cases from suspects with final alternative diagnoses. The first is lumbar puncture and the second MRI brain scanning. Typically patients with CJD have neither an excess ofwhite cells nor oligoclonal bands 102 in the cerebrospinal fluid (as TSEs are not inflammatory disorders), but about one-third have a raised protein, a nonspecific finding. However, the detection ofone particular protein, called 14-3-3 (an indicator or neuronal death) has now been shown in multiple studies to be a highly sensitive (-94%) and specific (-84%) marker ofsporadic CJD. " Unfortunately this test is less sensitive (-50%) in detecting variant CJDY However, recent work has reported that elevated CSF tau has a comparably high sensitivity and specificity in both sporadic and variant CJD (92% vs. 80% and 97% vs. 94% respectively)." CSF analysis of these two brain-specific proteins is performed at the CJD Surveillance Unit in Edinburgh (contact Dr Alison Green 01315373075), but should only be performed on patients with suspected CJD as the specificity will fall ifused as a screening test. MRI shows bilateral high signal on long-repetition time sequences (proton density and T2-weighted) in the striatum (caudate and putamen) in about two-thirds of sporadic CJD cases (Fig 2) , but only 7% ofcontrols." In variant CJD a different pattern is seen with the pulvinar of the thalamus showing prominent bilateral hyperintensity relative to other grey matter, a finding observed in over 80% of the cases tested and as yet no suspected cases with a final alternative diagnosis (Fig 2) . Fluid attenuated inversion recovery (FLAIR) is a relatively new form of MR imaging that is more sensitive than conventional sequences in sporadic and variant CJD. 14 Diffusion-weighted imaging (DWI), another novel technique, appears even better than FLAIR in sporadic CJD, 14 but too little data is available in variant CJD is assess its utility at present. The recognition of the usefulness ofCSF 14-3-3 and MRI in sporadic and variant CJD respectively led to their inclusion in recently revised WHO clinical diagnostic criteria (Figs 3 and  4 ). 15.16 Tonsil biopsy is a somewhat more controversial procedure, given its invasive nature, that has been shown to be useful in variant but not other forms ofCJD: in the former immunostaining Comment for the abnormal form ofPrP is usually positive, a finding that is claimed to be highly specific.17I believe that tonsil biopsy should only be considered in patients with a strong suspicion ofvariant CJD in whom MRI is negative.
CJD: the future?
It has been argued that CJD is the best understood of all neurodegenerative conditions, and certainly great strides have been made in understanding this disease in the past few decades. Despite this, the wish list for future breakthroughs is long, and includes a screening test for pre symptomatic cases, a method to exclude infectivity in blood and other tissues, noninvasive diagnostic tests highly accurate early in the clinical course, an effective treatment and, the holy grail, identification of the exact nature of the transmissible agent. Some believe that recent efforts to develop highly sensitive assays for PrP will be rewarded with a blood test for affected and presymptomatic individuals in the next few years. However, such views may be over-optimistic as it is not clear whether most patients with CJD have any potentially detectable abnormal PrP in the blood. We should also be cautious in raising our hopes too high after recent reports of patients being treated with quinacrine. 18 This compound has been reported to cure neuroblastoma cell lines infected with scrapie, but it is giant leap from the Petri dish to the hospital ward, and perhaps, a leap that should not have occurred without promising results from in-vivo animal studies. Still, it is encouraging that (well-funded) scientists are prepared, against what seems like massive odds, to search for a cure for a rare neurodegenerative disease rather than dismissing this as alchemy. But what of the search for the holy grail? Scientists from California and from Edinburgh s Neuropathogenesis Unit are leading the hunt, but have different ideas as to what they might find: the Americans believing that the agent will contain only protein and the Scots being sceptical of this view. Who will tum out to be right is anyone s guess, but what is certain is that unlocking the secret ofthe TSE agent will lead to new ideas for diagnostic tests and therapy, and will likely be helpful in our understanding of the more common disorders in which protein conformation seems to play an important role, such as Alzheimer s disease. 19 Martin Zeidler Department of Clinical Neurosciences Western General Hospital Crewe Road Edinburgh
